telavancin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
vancomycin related compounds	4116	372151-71-8

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

telavancin
arbelic
telavancin hydrochloride
vibativ
telavancin HCl

an anti-infective agent

Molecular weight: 1755.65
Formula: C80H106Cl2N11O27P
CLOGP: 0.78
LIPINSKI: 3
HAC: 38
HDO: 23
TPSA: 598.09
ALOGS: -5.08
ROTB: 30

Drug dosage:

None

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	0.11 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.20 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.07 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	6.70 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Sept. 11, 2009	FDA	THERAVANCE BIOPHARMA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypertensive heart disease	81.11	59.76	14	291	4192	79739891
Tubulointerstitial nephritis	79.17	59.76	20	285	38215	79705868
Acute kidney injury	66.30	59.76	34	271	519370	79224713
Klebsiella infection	62.69	59.76	14	291	15706	79728377

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01XA03	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER ANTIBACTERIALS Glycopeptide antibacterials
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
FDA EXT	N0000191280	Lipoglycopeptides
FDA EPC	N0000191281	Lipoglycopeptide Antibacterial
CHEBI has role	CHEBI:33281	antibiotics
CHEBI has role	CHEBI:36047	antibacterial drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Bacterial pneumonia	indication	53084003	DOID:874
Pneumonia due to Staphylococcus aureus	indication	441658007
Complicated Skin and Skin Structure Streptococcus Agalactiae Infection	indication
Complicated Skin and Skin Structure Streptococcus Pyogenes Infection	indication
Complicated Skin and Skin Structure Infection	indication
Complicated Skin and Skin Structure Enterococcus Faecalis Infection	indication
Complicated Skin and Skin Structure Staphylococcus Aureus Infection	indication
Torsades de pointes	contraindication	31722008
Hypertensive disorder	contraindication	38341003	DOID:10763
Chronic heart failure	contraindication	48447003
Diabetes mellitus	contraindication	73211009	DOID:9351
Kidney disease	contraindication	90708001	DOID:557
Prolonged QT interval	contraindication	111975006
Decompensated cardiac failure	contraindication	195111005
Impaired renal function disorder	contraindication	197663003
Pregnancy, function	contraindication	289908002
Pseudomembranous enterocolitis	contraindication	397683000
Congenital long QT syndrome	contraindication	442917000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	1.06	acidic
pKa2	2.59	acidic
pKa3	6.27	acidic
pKa4	7.41	acidic
pKa5	7.98	acidic
pKa6	10.14	acidic
pKa7	10.72	acidic
pKa8	11.49	acidic
pKa9	12.61	acidic
pKa10	12.69	acidic
pKa11	13.01	acidic
pKa12	13.37	acidic
pKa13	13.47	acidic
pKa14	12.0	Basic
pKa15	9.53	Basic
pKa16	8.33	Basic
pKa17	5.6	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 250MG BASE/VIAL	VIBATIV	CUMBERLAND PHARMS	N022110	Sept. 11, 2009	DISCN	POWDER	INTRAVENOUS	6635618	Sept. 11, 2023	METHOD FOR TREATING BACTERIAL INFECTION
EQ 750MG BASE/VIAL	VIBATIV	CUMBERLAND PHARMS	N022110	Sept. 11, 2009	RX	POWDER	INTRAVENOUS	6635618	Sept. 11, 2023	METHOD FOR TREATING BACTERIAL INFECTION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4029465	VUID
N0000180310	NUI
D06057	KEGG_DRUG
560130-42-9	SECONDARY_CAS_RN
4029465	VANDF
4029466	VANDF
C1453642	UMLSCUI
CHEBI:71229	CHEBI
CHEMBL507870	ChEMBL_ID
CHEMBL3301680	ChEMBL_ID
DB06402	DRUGBANK_ID
C487637	MESH_SUPPLEMENTAL_RECORD_UI
10925	IUPHAR_LIGAND_ID
8504	INN_ID
XK134822Z0	UNII
3081362	PUBCHEM_CID
473837	RXNORM
167756	MMSL
26725	MMSL
30522	MMSL
d07483	MMSL
013290	NDDF
013291	NDDF
443552009	SNOMEDCT_US
443553004	SNOMEDCT_US
768493001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Vibativ	HUMAN PRESCRIPTION DRUG LABEL	1	52118-001	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 mg	INTRAVENOUS	NDA	33 sections
Vibativ	HUMAN PRESCRIPTION DRUG LABEL	1	52118-002	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 mg	INTRAVENOUS	NDA	33 sections
VIBATIV	HUMAN PRESCRIPTION DRUG LABEL	1	66220-315	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 mg	INTRAVENOUS	NDA	30 sections
VIBATIV	HUMAN PRESCRIPTION DRUG LABEL	1	66220-315	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 mg	INTRAVENOUS	NDA	30 sections